
Keywords: ALS; amyotrophic lateral sclerosis; ASO; antisense oligonucleotide; BBB; blood brain barrier; CREB; cyclic AMP response element binding protein; FDA; Food and Drug Administration; GSK-3; glycogen synthase kinase 3; HDAC; histone deacetylase; hnRNP A1; het